# To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

> **NCT01900249** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 204 (actual)

## Conditions studied

- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** R348 Ophthalmic Solution, 0.2%
- **DRUG:** R348 Ophthalmic Solution, 0.5%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01900249
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2016-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900249, "To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01900249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*